NO20040933L - Nye gamma-sekretaseinhibitorer. - Google Patents
Nye gamma-sekretaseinhibitorer.Info
- Publication number
- NO20040933L NO20040933L NO20040933A NO20040933A NO20040933L NO 20040933 L NO20040933 L NO 20040933L NO 20040933 A NO20040933 A NO 20040933A NO 20040933 A NO20040933 A NO 20040933A NO 20040933 L NO20040933 L NO 20040933L
- Authority
- NO
- Norway
- Prior art keywords
- secretase inhibitors
- novel gamma
- gamma
- novel
- secretase
- Prior art date
Links
- 239000003540 gamma secretase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31001301P | 2001-08-03 | 2001-08-03 | |
| US35551002P | 2002-02-06 | 2002-02-06 | |
| PCT/US2002/024323 WO2003014075A2 (en) | 2001-08-03 | 2002-08-01 | Novel gamma secretase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20040933L true NO20040933L (no) | 2004-03-03 |
Family
ID=26977148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20040933A NO20040933L (no) | 2001-08-03 | 2004-03-03 | Nye gamma-sekretaseinhibitorer. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6683091B2 (no) |
| EP (1) | EP1492765B1 (no) |
| JP (1) | JP4418671B2 (no) |
| KR (1) | KR20040019094A (no) |
| CN (1) | CN1304390C (no) |
| AR (1) | AR034390A1 (no) |
| AT (1) | ATE515495T1 (no) |
| AU (1) | AU2002324582B9 (no) |
| BR (1) | BR0211698A (no) |
| CA (1) | CA2455863C (no) |
| CO (1) | CO5550419A2 (no) |
| HU (1) | HUP0600673A3 (no) |
| IL (1) | IL159848A0 (no) |
| MX (1) | MXPA04001014A (no) |
| NO (1) | NO20040933L (no) |
| PL (1) | PL372212A1 (no) |
| RU (1) | RU2004106540A (no) |
| TW (1) | TWI242555B (no) |
| WO (1) | WO2003014075A2 (no) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6984522B2 (en) | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
| US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
| EP1453516A2 (de) * | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
| US7399775B2 (en) | 2001-12-27 | 2008-07-15 | Daiichi Pharmaceutical Co., Ltd. | β-amyloid protein production/secretion inhibitor |
| US7521481B2 (en) | 2003-02-27 | 2009-04-21 | Mclaurin Joanne | Methods of preventing, treating and diagnosing disorders of protein aggregation |
| RU2336270C2 (ru) | 2003-06-30 | 2008-10-20 | Дайити Фармасьютикал Ко., Лтд. | Гетероциклические метилсульфоновые производные |
| MXPA06001558A (es) * | 2003-08-08 | 2006-05-15 | Schering Corp | Inhibidores de amina ciclica bace-1 que poseen un sustituyente heterociclico. |
| EP1660443B1 (en) * | 2003-08-08 | 2009-03-04 | Schering Corporation | Cyclic amine bace-1 inhibitors having a benzamide substituent |
| ATE552851T1 (de) | 2004-02-03 | 2012-04-15 | Univ Michigan | Zusammensetzungen zur behandlung von brust- und bauchspeicheldrüsenkrebs |
| CA2554779A1 (en) * | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
| KR20070010144A (ko) * | 2004-04-05 | 2007-01-22 | 쉐링 코포레이션 | 신규한 감마 세크레타제 억제제 |
| EP1758884A2 (en) * | 2004-05-20 | 2007-03-07 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| CN101602741A (zh) * | 2004-06-30 | 2009-12-16 | 先灵公司 | 作为γ-分泌酶抑制剂的取代的N-芳基磺酰基杂环胺 |
| ATE491693T1 (de) * | 2004-07-22 | 2011-01-15 | Schering Corp | Substituierte amide als inhibitoren der beta- sekretase |
| ES2413705T3 (es) * | 2005-04-08 | 2013-07-17 | Daiichi Sankyo Company, Limited | Derivado de piridilmetilsulfona |
| US20060252073A1 (en) * | 2005-04-18 | 2006-11-09 | Regents Of The University Of Michigan | Compositions and methods for the treatment of cancer |
| CA2610828A1 (en) * | 2005-06-14 | 2006-12-28 | Schering Corporation | Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| US7723112B2 (en) | 2005-10-31 | 2010-05-25 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| EP2511298B1 (en) | 2005-10-31 | 2019-01-16 | Oncomed Pharmaceuticals, Inc. | Compositions and Methods for Treating Cancer based on human FZD receptors |
| US7723477B2 (en) | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
| MX2008009414A (es) | 2006-01-20 | 2008-10-01 | Schering Corp | Arilsulfonas carbociclicas y heterociclicas como inhibidores de gamma secretasa. |
| EP1998785A4 (en) * | 2006-02-21 | 2009-06-17 | Univ Michigan | TREATMENT OF CANCER BY AN ANTAGONIST OF THE HEDGEHOG SIGNALING PATH |
| US8133857B2 (en) * | 2006-03-07 | 2012-03-13 | The Brigham and Women's FHospital, Inc. | NOTCH inhibition in the treatment of atherosclerosis |
| US9567396B2 (en) | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| TW200813054A (en) * | 2006-06-02 | 2008-03-16 | Elan Pharm Inc | Fused, tricyclic sulfonamide inhibitors of gamma secretase |
| US8278345B2 (en) | 2006-11-09 | 2012-10-02 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| JP5523107B2 (ja) | 2006-11-30 | 2014-06-18 | プロビオドルグ エージー | グルタミニルシクラーゼの新規阻害剤 |
| WO2008092002A2 (en) | 2007-01-24 | 2008-07-31 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
| EP2481408A3 (en) | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| WO2008128985A1 (en) | 2007-04-18 | 2008-10-30 | Probiodrug Ag | Thiourea derivatives as glutaminyl cyclase inhibitors |
| CN101754960A (zh) | 2007-07-05 | 2010-06-23 | 先灵公司 | 四氢吡喃并色烯γ-分泌酶抑制剂 |
| CA2693216A1 (en) * | 2007-07-17 | 2009-01-22 | Schering Corporation | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors |
| TWI506037B (zh) | 2008-09-26 | 2015-11-01 | Oncomed Pharm Inc | 捲曲結合劑類及彼等之用途 |
| CA2742317A1 (en) * | 2008-11-06 | 2010-05-14 | Schering Corporation | Gamma secretase modulators |
| WO2010138901A1 (en) * | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Carboxylic acid-containing compounds, derivatives thereof, and related methods of use |
| US20120129189A1 (en) * | 2009-07-17 | 2012-05-24 | Chulan Kwon | Methods of Controlling Cell Proliferation |
| MX2012002993A (es) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Derivados heterociclicos como inhibidores de ciclasa glutaminilo. |
| WO2011044184A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| WO2011044185A2 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Pentafluorosulfur imino heterocyclic compounds as bace-1 inhibitors, compositions, and their use |
| WO2011044187A1 (en) | 2009-10-08 | 2011-04-14 | Schering Corporation | Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| EP2493497A4 (en) | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| TWI535445B (zh) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Ｗｎｔ拮抗劑及治療和篩選方法 |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| US8269019B2 (en) | 2010-03-10 | 2012-09-18 | Probiodrug Ag | Inhibitors |
| WO2011123785A2 (en) | 2010-04-01 | 2011-10-06 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
| WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
| JP5275315B2 (ja) * | 2010-10-01 | 2013-08-28 | 学校法人近畿大学 | 新規化合物及びβ−セクレターゼ阻害剤 |
| JP6063870B2 (ja) | 2010-11-08 | 2017-01-18 | ライセラ・コーポレイション | ＲＯＲγ活性の阻害用のＮ−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療 |
| ES2570167T3 (es) | 2011-03-16 | 2016-05-17 | Probiodrug Ag | Derivados de benzimidazol como inhibidores de glutaminil ciclasa |
| US9145426B2 (en) | 2011-04-07 | 2015-09-29 | Merck Sharp & Dohme Corp. | Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use |
| WO2012138734A1 (en) | 2011-04-07 | 2012-10-11 | Merck Sharp & Dohme Corp. | C5-c6 oxacyclic-fused thiadiazine dioxide compounds as bace inhibitors, compositions, and their use |
| KR20140054295A (ko) | 2011-08-22 | 2014-05-08 | 머크 샤프 앤드 돔 코포레이션 | Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도 |
| WO2013059302A1 (en) | 2011-10-17 | 2013-04-25 | Nationwide Children's Hospital, Inc. | Products and methods for aortic abdominal aneurysm |
| WO2013169864A2 (en) | 2012-05-08 | 2013-11-14 | Lycera Corporation | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE |
| MX367341B (es) | 2012-05-08 | 2019-08-14 | Merck Sharp & Dohme | Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades. |
| EP2911691B1 (en) | 2012-10-23 | 2018-10-10 | OncoMed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using wnt pathway-binding agents |
| JP2016510411A (ja) | 2013-02-04 | 2016-04-07 | オンコメッド ファーマシューティカルズ インコーポレイテッド | Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング |
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| US9809561B2 (en) | 2013-12-20 | 2017-11-07 | Merck Sharp & Dohme Corp. | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease |
| US9663502B2 (en) | 2013-12-20 | 2017-05-30 | Lycera Corporation | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease |
| WO2015095792A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease |
| AU2015222917A1 (en) | 2014-02-27 | 2016-09-15 | Lycera Corporation | Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma and related therapeutic methods |
| JP6523337B2 (ja) | 2014-05-05 | 2019-05-29 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物 |
| JP6728061B2 (ja) | 2014-05-05 | 2020-07-22 | リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ | ＲＯＲγアゴニストとして用いるテトラヒドロキノリンスルホンアミド及び関連化合物ならびに疾患の治療 |
| CN104027810B (zh) * | 2014-06-30 | 2016-02-10 | 王涛 | 一种构建先天性肝内胆管发育不良综合征动物模型的方法 |
| WO2016130818A1 (en) | 2015-02-11 | 2016-08-18 | Merck Sharp & Dohme Corp. | SUBSTITUTED PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF |
| AU2016257997A1 (en) | 2015-05-05 | 2017-11-09 | Lycera Corporation | Dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease |
| US10611740B2 (en) | 2015-06-11 | 2020-04-07 | Lycera Corporation | Aryl dihydro-2H-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease |
| US10344000B2 (en) | 2015-10-27 | 2019-07-09 | Merck Sharp & Dohme Corp. | Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof |
| WO2017075185A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof |
| WO2017075182A1 (en) | 2015-10-27 | 2017-05-04 | Merck Sharp & Dohme Corp. | Substituted indazole compounds as rorgammat inhibitors and uses thereof |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| WO2020016377A1 (en) | 2018-07-19 | 2020-01-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination for treating cancer |
| EP4244391A1 (en) | 2020-11-16 | 2023-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for predicting and treating uveal melanoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1328176A (fr) * | 1962-07-06 | 1963-05-24 | Monsanto Chemicals | Procédé de préparation de dérivés des hydroquinoléines |
| JPS556321A (en) * | 1978-06-27 | 1980-01-17 | Konishiroku Photo Ind Co Ltd | Color photographic material |
| JPS6395447A (ja) * | 1986-10-11 | 1988-04-26 | Konica Corp | 色素画像の光堅牢性が改良されたハロゲン化銀写真感光材料 |
| NZ509439A (en) * | 1998-07-30 | 2002-10-25 | Warner Lambert Co | Tricyclic sulfonamides and their derivatives as inhibitors of matrix metalloproteinases |
| MXPA01008606A (es) * | 1999-02-26 | 2003-05-05 | Merck & Co Inc | Compuestos de sulfonamida novedosos y uso de los mismos. |
| IL138686A0 (en) * | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
| WO2001027108A1 (en) * | 1999-10-08 | 2001-04-19 | Bristol-Myers Squibb Pharma Company | AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION |
-
2002
- 2002-08-01 CN CNB028152603A patent/CN1304390C/zh not_active Expired - Fee Related
- 2002-08-01 KR KR10-2004-7001505A patent/KR20040019094A/ko not_active Withdrawn
- 2002-08-01 CA CA2455863A patent/CA2455863C/en not_active Expired - Fee Related
- 2002-08-01 HU HU0600673A patent/HUP0600673A3/hu unknown
- 2002-08-01 MX MXPA04001014A patent/MXPA04001014A/es active IP Right Grant
- 2002-08-01 JP JP2003519025A patent/JP4418671B2/ja not_active Expired - Fee Related
- 2002-08-01 BR BR0211698-7A patent/BR0211698A/pt not_active IP Right Cessation
- 2002-08-01 AU AU2002324582A patent/AU2002324582B9/en not_active Ceased
- 2002-08-01 US US10/210,829 patent/US6683091B2/en not_active Expired - Fee Related
- 2002-08-01 IL IL15984802A patent/IL159848A0/xx unknown
- 2002-08-01 AT AT02759233T patent/ATE515495T1/de not_active IP Right Cessation
- 2002-08-01 AR ARP020102926A patent/AR034390A1/es unknown
- 2002-08-01 WO PCT/US2002/024323 patent/WO2003014075A2/en not_active Ceased
- 2002-08-01 PL PL02372212A patent/PL372212A1/xx unknown
- 2002-08-01 EP EP02759233A patent/EP1492765B1/en not_active Expired - Lifetime
- 2002-08-01 TW TW091117313A patent/TWI242555B/zh active
- 2002-08-01 RU RU2004106540/04A patent/RU2004106540A/ru not_active Application Discontinuation
-
2004
- 2004-01-21 CO CO04003799A patent/CO5550419A2/es not_active Application Discontinuation
- 2004-03-03 NO NO20040933A patent/NO20040933L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003014075A3 (en) | 2004-09-30 |
| HUP0600673A2 (en) | 2006-12-28 |
| HUP0600673A3 (en) | 2011-08-29 |
| MXPA04001014A (es) | 2004-05-27 |
| KR20040019094A (ko) | 2004-03-04 |
| AR034390A1 (es) | 2004-02-25 |
| RU2004106540A (ru) | 2005-07-27 |
| TWI242555B (en) | 2005-11-01 |
| EP1492765A2 (en) | 2005-01-05 |
| ATE515495T1 (de) | 2011-07-15 |
| US6683091B2 (en) | 2004-01-27 |
| CO5550419A2 (es) | 2005-08-31 |
| JP2005504760A (ja) | 2005-02-17 |
| CA2455863C (en) | 2010-10-12 |
| AU2002324582B2 (en) | 2006-01-05 |
| CA2455863A1 (en) | 2003-02-20 |
| JP4418671B2 (ja) | 2010-02-17 |
| BR0211698A (pt) | 2004-11-09 |
| AU2002324582B9 (en) | 2006-02-16 |
| EP1492765B1 (en) | 2011-07-06 |
| PL372212A1 (en) | 2005-07-11 |
| IL159848A0 (en) | 2004-06-20 |
| WO2003014075A2 (en) | 2003-02-20 |
| CN1630651A (zh) | 2005-06-22 |
| US20030135044A1 (en) | 2003-07-17 |
| CN1304390C (zh) | 2007-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20034308L (no) | Nye tyrokinase-inhibitorer | |
| NO20035428D0 (no) | Nye anti-ineffektiver | |
| NO20034992D0 (no) | Nye 4-aninlinokinolin-3-karboksamider | |
| ATE308544T1 (de) | N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren | |
| NO20040014L (no) | Nye forbindelser | |
| NO20041003L (no) | Nye forbindelser | |
| NO20034665L (no) | Nye forbindelser | |
| DE60234125D1 (de) | E inhibitoren | |
| NO20044432L (no) | Nye forbindelser | |
| ATE304015T1 (de) | Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren | |
| NO20043696L (no) | Gamma-sekretaseinhibitorer | |
| NO20034970D0 (no) | Nye arylheteroalkylaminderivater | |
| NO20053248D0 (no) | Kerosenblanding. | |
| NO20034695D0 (no) | Nye sammensetninger | |
| NO20041185L (no) | Nye sykloheksylsulfoner | |
| NO20052248D0 (no) | Svivelstykkesystem. | |
| NO20030274D0 (no) | Nye aryleten-sulfonamider | |
| NO20051500D0 (no) | Substituerte heterocyklylpyrimidiner. | |
| NO20035248D0 (no) | Nye fenylalkyloksy-fenyl derivater | |
| ITMI20032170A1 (it) | Tagliacimosse. | |
| NO20025902L (no) | Nye fenylpiperaziner | |
| NO20051497D0 (no) | Beta-laktamaseinhibitorprodrug. | |
| NO20044098L (no) | Nye forbindelser | |
| NO20040913L (no) | Nye 2,4-diaminotiazolderivater | |
| NO20050026L (no) | Nye benzodioksoler |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |